Dongrui Manufacturing (02348) fell by more than 10%, down 12.88% at press time, to HK$1.15, with a turnover of HK$1.54 million.
The Zhitong Finance App learned that Dongrui Manufacturing (02348) fell by more than 10%, down 12.88% at press time, to HK$1.15, with a turnover of HK$1.54 million.
According to the news, the company announced its annual results for the year ended December 31, 2023. The group achieved revenue of 1.151 billion yuan (RMB, same below), a year-on-year decrease of 9.9%; profit attributable to shareholders of 326 million yuan, a year-on-year decrease of 8.95%; basic profit per share of 0.2174 yuan; and proposed to pay a final dividend of HK$0.065 per share.
According to the announcement, sales of intermediates and APIs were RMB 129 million, down 7.8% from last year, and sales decreased by RMB 11.022 million; sales of proprietary drugs were RMB 1,022 million, down 10.2% from last year, and sales decreased by RMB 116 million. The decline in sales of intermediates and APIs was mainly affected by the relocation and discontinuation of production of the Tianling Road plant of Suzhou Dongrui Pharmaceutical. The decrease in sales of proprietary drugs was mainly affected by the collection of “Annexi” (losartan potassium hydrochlorothiazide tablets) and “Ammeipine” (levamlodipine benzenesulfonate tablets) from Suzhou Dongrui Pharmaceutical.